INTERNATIONAL PATENT: PFIZER INC. FILES APPLICATION FOR "TMPRSS2-ERG AND RB1 AS PREDICTIVE BIOMARKERS FOR TREATMENT WITH A PARP INHIBITOR"

GENEVA, Oct. 13 -- PFIZER INC. (66 Hudson Boulevard EastNew York, New York 10001-2192) filed a patent application (PCT/IB2025/053416) for "TMPRSS2-ERG AND RB1 AS PREDICTIVE BIOMARKERS FOR TREATMENT WITH A PARP INHIBITOR" on Apr 01, 2025. With publication no. WO/2025/210510, the details related to the patent application was published on Oct 09, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): LAIRD, Alan Douglas (c/o Pfizer Inc.10777 Science Center DriveSan Diego, California 92121)

Abstract: This invention relates to methods for selecting patients having prostate cancer for treatment with a P...